Metric Analysis: Guardant Health Inc (GH)’s Key Ratios in the Limelight

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Guardant Health Inc (NASDAQ: GH) closed at $27.99 up 2.12% from its previous closing price of $27.41. In other words, the price has increased by $2.12 from its previous closing price. On the day, 2.35 million shares were traded. GH stock price reached its highest trading level at $28.32 during the session, while it also had its lowest trading level at $26.74.

Ratios:

For a deeper understanding of Guardant Health Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.66 and its Current Ratio is at 5.95. In the meantime, Its Debt-to-Equity ratio is 19.73 whereas as Long-Term Debt/Eq ratio is at 19.33.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 18 ’24 when Kalia Kumud bought 2,187 shares for $17.82 per share. The transaction valued at 38,963 led to the insider holds 12,722 shares of the business.

Joyce Meghan V. sold 100 shares of GH for $1,905 on Mar 04 ’24. The Director now owns 4,521 shares after completing the transaction at $19.05 per share. On Dec 04 ’23, another insider, Joyce Meghan V., who serves as the Director of the company, sold 100 shares for $26.34 each. As a result, the insider received 2,634 and left with 4,422 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 3425108224 and an Enterprise Value of 3743562240. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.67 while its Price-to-Book (P/B) ratio in mrq is 49.92. Its current Enterprise Value per Revenue stands at 6.201 whereas that against EBITDA is -9.322.

Stock Price History:

Over the past 52 weeks, GH has reached a high of $41.06, while it has fallen to a 52-week low of $15.81. The 50-Day Moving Average of the stock is 37.81%, while the 200-Day Moving Average is calculated to be 13.62%.

Shares Statistics:

For the past three months, GH has traded an average of 2.27M shares per day and 2761380 over the past ten days. A total of 121.63M shares are outstanding, with a floating share count of 115.99M. Insiders hold about 5.21% of the company’s shares, while institutions hold 93.60% stake in the company. Shares short for GH as of 1715731200 were 10759821 with a Short Ratio of 4.73, compared to 1713139200 on 9556452. Therefore, it implies a Short% of Shares Outstanding of 10759821 and a Short% of Float of 9.17.

Earnings Estimates

The stock of Guardant Health Inc (GH) is currently in the spotlight, with 17.0 analysts actively rating and assessing its market standing.On average, analysts expect EPS of -$0.76 for the current quarter, with a high estimate of -$0.54 and a low estimate of -$0.95, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.5 and low estimates of -$0.9.

Analysts are recommending an EPS of between -$2.43 and -$3.65 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$2.75, with 18.0 analysts recommending between -$1.45 and -$3.41.

Revenue Estimates

A total of 20 analysts believe the company’s revenue will be $162.68M this quarter.It ranges from a high estimate of $166M to a low estimate of $157.2M. As of the current estimate, Guardant Health Inc’s year-ago sales were $137.15MFor the next quarter, 20 analysts are estimating revenue of $168.97M. There is a high estimate of $173M for the next quarter, whereas the lowest estimate is $164.9M.

A total of 21 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $685.99M, while the lowest revenue estimate was $678M, resulting in an average revenue estimate of $681.31M. In the same quarter a year ago, actual revenue was $563.95MBased on 21 analysts’ estimates, the company’s revenue will be $813.55M in the next fiscal year. The high estimate is $866.7M and the low estimate is $758.2M.

Most Popular